High affinity dopamine D2 and 5-HT1A receptor partial agonist (Ki values are ~1.64 and 5.59 nM respectively). Also 5-HT2A antagonist (Ki = 8.7 nM). Suppresses morphine-induced emesis in vivo. Atypical antipsychotic.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 448.39. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.23 mL||11.15 mL||22.3 mL|
|5 mM||0.45 mL||2.23 mL||4.46 mL|
|10 mM||0.22 mL||1.12 mL||2.23 mL|
|50 mM||0.04 mL||0.22 mL||0.45 mL|
References are publications that support the products' biological activity.
Davies et al (2004) Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 10 317 PMID: 15592581
Shiokawa et al (2007) Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. Eur.J.Pharmacol. 570 108 PMID: 17678644
If you know of a relevant reference for Aripiprazole, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Aripiprazole, supplier, high, affinity, dopamine, D2, 5-ht1a, 5-ht2a, partial, agonists, antagonists, antipsychotic, D2, Receptors, 5-HT1A, Receptors, 5-HT2A, Receptors, D2, Receptors, Tocris Bioscience
Citations for Aripiprazole
Citations are publications that use Tocris products.
Currently there are no citations for Aripiprazole. Do you know of a great paper that uses Aripiprazole from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.